ATE74271T1 - Ketonderivate als arzneimittel zur behandlung oder vorbeugung des entzugssyndromes. - Google Patents

Ketonderivate als arzneimittel zur behandlung oder vorbeugung des entzugssyndromes.

Info

Publication number: ATE74271T1
Authority: AT; Austria
Prior art keywords: prevention; medications; treatment; withdrawal syndrome; ketone derivatives
Prior art date: 1986-11-21

Application number

AT87310289T

Other languages

English (en)

Inventor

Michael Brian Tyers

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-11-21

Filing date

1987-11-20

Publication date

1992-04-15

1987-11-20 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

1992-04-15 Application granted granted Critical

1992-04-15 Publication of ATE74271T1 publication Critical patent/ATE74271T1/de

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, ***e
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Toxicology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AT87310289T 1986-11-21 1987-11-20 Ketonderivate als arzneimittel zur behandlung oder vorbeugung des entzugssyndromes. ATE74271T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB868627909A GB8627909D0 (en)	1986-11-21	1986-11-21	Medicaments
EP87310289A EP0278161B1 (de)	1986-11-21	1987-11-20	Ketonderivate als Arzneimittel zur Behandlung oder Vorbeugung des Entzugssyndromes

Publications (1)

Publication Number	Publication Date
ATE74271T1 true ATE74271T1 (de)	1992-04-15

Family

ID=10607734

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT87310289T ATE74271T1 (de)	1986-11-21	1987-11-20	Ketonderivate als arzneimittel zur behandlung oder vorbeugung des entzugssyndromes.

Country Status (16)

Country	Link
US (1)	US4847281A (de)
EP (1)	EP0278161B1 (de)
JP (1)	JPH0830008B2 (de)
KR (1)	KR950010148B1 (de)
AT (1)	ATE74271T1 (de)
AU (1)	AU608788B2 (de)
CY (1)	CY1694A (de)
DE (1)	DE3778008D1 (de)
DK (1)	DK612787A (de)
ES (1)	ES2033879T3 (de)
GB (1)	GB8627909D0 (de)
GR (1)	GR3004252T3 (de)
HK (1)	HK36793A (de)
IE (1)	IE61033B1 (de)
PH (1)	PH24934A (de)
ZA (1)	ZA878702B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0279114B2 (de) *	1986-11-21	1995-08-23	Glaxo Group Limited	Arzneimittel zur Behandlung oder Vorbeugung des Entzugssyndromes
US5198447A (en) *	1986-11-21	1993-03-30	Glaxo Group Limited	Medicaments
DE3822792C2 (de) *	1987-07-11	1997-11-27	Sandoz Ag	Neue Verwendung von 5HT¶3¶-Antagonisten
US5198459A (en) *	1987-07-11	1993-03-30	Sandoz Ltd.	Use of 5HT-3 antagonists in preventing or reducing dependency on dependency-inducing agents
US5272168A (en) *	1987-07-11	1993-12-21	Sandoz Ltd.	Use of 5HT-3 antagonists in preventing or reducing dependency on dependency-inducing agents
GB8820650D0 (en) *	1988-09-01	1988-10-05	Glaxo Group Ltd	Medicaments
US5292752A (en) *	1989-12-21	1994-03-08	Merrell Dow Pharmaceuticals Inc.	Antithrombotic compounds
US5225407A (en) *	1990-02-22	1993-07-06	Glaxo Group Limited	5-HT3 receptor antagonists for the treatment of autism
US5397782A (en) *	1990-06-13	1995-03-14	Janssen Pharmaceutica N.V.	Method of treating addiction to alcohol
CA2112487C (en) *	1991-06-26	2003-04-15	James W. Young	Method and compositions for treating emesis, nausea and other disorders using optically pure r(+) ondansetron
GB9310756D0 (en) *	1993-05-25	1993-07-14	Glaxo Lab Sa	Compositions
US5726644A (en) *	1995-06-30	1998-03-10	Philips Electronics North America Corporation	Lighting control system with packet hopping communication
US5824684A (en) *	1997-02-21	1998-10-20	Synapse Pharmaceuticals International, Inc.	Method for treating drug and alcohol addiction
US20080004260A1 (en) *	2006-06-29	2008-01-03	Transcept Pharmaceuticals, Inc.	Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions
CN102307895A (zh) *	2008-12-04	2012-01-04	里兰斯坦福初级大学理事会	用于治疗或预防***停药症状的方法和组合物
US20100298397A1 (en) *	2009-05-19	2010-11-25	Singh Nikhilesh N	Method of treatment of obsessive compulsive disorder with ondansetron
US20110288115A1 (en) *	2010-05-24	2011-11-24	Avmedis Llc	Treatment of vagally-mediated spectrum disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4499096A (en) *	1983-11-18	1985-02-12	Lotsof Howard S	Rapid method for interrupting the narcotic addiction syndrome
NO164025C (no) *	1984-01-25	1990-08-22	Glaxo Group Ltd	Analogifremgangsmaate for fremstilling av terapeutisk aktive 3-imidazolylmetyl-tetrahydrokarbazolon-derivater.
DE201165T1 (de) *	1985-03-14	1989-04-20	Beecham Group P.L.C., Brentford, Gb	Arzneimittel zur behandlung von emesis, anxietas und "irritable bowel syndrome".
GB8516083D0 (en) *	1985-06-25	1985-07-31	Glaxo Group Ltd	Heterocyclic compounds
NL8701682A (nl) *	1986-07-30	1988-02-16	Sandoz Ag	Werkwijze voor het therapeutisch toepassen van serotonine antagonisten, aktieve verbindingen en farmaceutische preparaten die deze verbindingen bevatten.
EP0272052B1 (de) *	1986-12-16	1992-07-08	A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation)	Angstlösende N-(1-Azabicyclo[2.2.2)oct-3-yl)benzamide und -thiobenzamide
DE3822792C2 (de) *	1987-07-11	1997-11-27	Sandoz Ag	Neue Verwendung von 5HT¶3¶-Antagonisten

1986
- 1986-11-21 GB GB868627909A patent/GB8627909D0/en active Pending
1987
- 1987-11-20 ES ES87310289T patent/ES2033879T3/es not_active Expired - Lifetime
- 1987-11-20 DE DE8787310289T patent/DE3778008D1/de not_active Expired - Lifetime
- 1987-11-20 JP JP62293894A patent/JPH0830008B2/ja not_active Expired - Lifetime
- 1987-11-20 PH PH36099A patent/PH24934A/en unknown
- 1987-11-20 AT AT87310289T patent/ATE74271T1/de not_active IP Right Cessation
- 1987-11-20 EP EP87310289A patent/EP0278161B1/de not_active Expired - Lifetime
- 1987-11-20 IE IE315687A patent/IE61033B1/en not_active IP Right Cessation
- 1987-11-20 ZA ZA878702A patent/ZA878702B/xx unknown
- 1987-11-20 DK DK612787A patent/DK612787A/da not_active Application Discontinuation
- 1987-11-20 AU AU81443/87A patent/AU608788B2/en not_active Ceased
- 1987-11-20 KR KR1019870013069A patent/KR950010148B1/ko not_active IP Right Cessation
- 1987-11-20 US US07/123,369 patent/US4847281A/en not_active Expired - Lifetime
1992
- 1992-04-02 GR GR920400436T patent/GR3004252T3/el unknown
1993
- 1993-04-15 HK HK367/93A patent/HK36793A/xx not_active IP Right Cessation
1994
- 1994-01-14 CY CY169494A patent/CY1694A/xx unknown

Also Published As

Publication number	Publication date
EP0278161A1 (de)	1988-08-17
AU8144387A (en)	1988-05-26
KR880005930A (ko)	1988-07-21
ZA878702B (en)	1988-09-28
DK612787A (da)	1988-05-22
ES2033879T3 (es)	1995-04-01
EP0278161B1 (de)	1992-04-01
JPH0830008B2 (ja)	1996-03-27
US4847281A (en)	1989-07-11
DK612787D0 (da)	1987-11-20
JPS63185927A (ja)	1988-08-01
HK36793A (en)	1993-04-23
IE873156L (en)	1988-05-21
IE61033B1 (en)	1994-09-07
KR950010148B1 (ko)	1995-09-11
DE3778008D1 (de)	1992-05-07
CY1694A (en)	1994-01-14
PH24934A (en)	1990-12-26
AU608788B2 (en)	1991-04-18
GB8627909D0 (en)	1986-12-31
GR3004252T3 (de)	1993-03-31

Legal Events

Date	Code	Title	Description
1992-10-15	UEP	Publication of translation of european patent specification
2005-08-15	REN	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE74271T1 (de)	1992-04-15	Ketonderivate als arzneimittel zur behandlung oder vorbeugung des entzugssyndromes.
HK1002825A1 (en)	1998-09-18	Use of sertindole for the treatment of schizophrenia sertindole
NO924502L (no)	1992-11-23	Ny anvendelse av difenylbutyl-piperazinkarboksamider ved behandling av stoffmisbruklidelser
KR930702000A (ko)	1993-09-08	노년기 치매, 식용항진, 편두통, 또는 식용불량의 치료를 위한 파로세틴의 사용
HU9603042D0 (en)	1997-01-28	Use of certain methanebisphosphonic acid derivatives to prevent or for treatment of prosthesis loosening and prosthesis migration
NO952906D0 (no)	1995-07-21	Farmasöytisk formulering for behandling av nikotinavhengighet
ZA879458B (en)	1988-11-30	Medicaments
KR950701221A (ko)	1995-03-23	물질 남용 장해 치료제
ZA925146B (en)	1993-08-16	Pharmaceutical agent for treatment of withdrawal symptoms.
FR2673105B1 (fr)	1995-01-13	Nouvelles compositions pharmaceutiques, notamment pour le traitement des colopathies fonctionnelles, et procedes de preparation de compositions et de medicaments, notamment pour le traitement de ces affections.
DE338532T1 (de)	1990-05-03	Tricyclische aromatische n-alkylamino derivaten zur behandlung von arzneimittel resistent protozuen infektionen.
IE873231L (en)	1988-05-28	Medicaments
IT1296613B1 (it)	1999-07-14	Farmaco per la cura dell'ircismo contenente un adrenocorticosteroide.
NO922635D0 (no)	1992-07-03	Ny anvendelse av benzimidazolin-2-okso-1-karboksylsyrederivater
KR940003550A (ko)	1994-03-12	노인성 치매 예방 및 치료방법
MX9703032A (es)	1997-12-31	Nuevas aplicaciones del 5-etoxicarbonil-2,4,6-trimetil-1,4-dihidropiridina-3-carboxi lato de 2-[n-(1,2-benzisotiazolil-3(2h) ona-1,1-dioxido]etilo.
NO169182C (no)	1992-05-20	Doseringsbeholder for opptak og levering av midler for behandling av toey.
ITMI910442V0 (it)	1991-05-22	Struttura di zoccolo ortopedico, o simile, in particolare per la prevenzione o la cura del valgismo dell'alluce
FR2674752B1 (fr)	1995-03-10	Utilisation de 4-amino-1-(2-pyridyl)piperidines pour la preparation de medicaments pour le traitement et la prophylaxie des etats decoulant d'un dysfonctionnement du systeme serotoninergique.